CytomX Therapeutics, Inc. (CTMX): Capital Expenditures
$220.0K
Year ended 2025-12-31
$74.0K
Trailing 12 months to 2026-06-30
-49.8%
3-year compound annual growth
-37.5%
5-year compound annual growth
-18.0%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $220.0K | -29.0% | 2026-03-16, From 2025-01-01 |
| 2024-12-31 | $310.0K | -63.1% | 2026-03-16, From 2024-01-01 |
| 2023-12-31 | $840.0K | -51.7% | 2025-03-06, From 2023-01-01 |
| 2022-12-31 | $1.74M | +8.1% | 2024-03-11, From 2022-01-01 |
| 2021-12-31 | $1.61M | -30.3% | 2023-03-27, From 2021-01-01 |
| 2020-12-31 | $2.31M | -34.0% | 2023-03-27, From 2020-01-01 |
| 2019-12-31 | $3.50M | -7.7% | 2023-03-27, From 2019-01-01 |
| 2018-12-31 | $3.79M | +143.0% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $1.56M | -28.4% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $2.18M | +36.5% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $1.59M | -4.1% | 2018-03-07, From 2015-01-01 |
| 2014-12-31 | $1.66M | +127.2% | 2017-03-02, From 2014-01-01 |
| 2013-12-31 | $732.0K | n/a | 2016-03-07, From 2013-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | 2025-12-31 | $220.0K | -29.0% |
| AbCellera Biologics Inc. (ABCL) | 2025-12-31 | $42.77M | -45.4% |
| Eton Pharmaceuticals, Inc. (ETON) | 2025-12-31 | $333.0K | n/m |
| Bicycle Therapeutics PLC (BCYC) | 2025-12-31 | $2.35M | +90.3% |
| Assembly Biosciences, Inc. (ASMB) | 2025-12-31 | $66.0K | +135.7% |
| ADC Therapeutics SA (ADCT) | 2025-12-31 | $264.0K | -69.6% |
| Viridian Therapeutics, Inc. (VRDN) | 2025-12-31 | $495.0K | -3.1% |
| Arcturus Therapeutics Holdings Inc. (ARCT) | 2025-12-31 | $230.0K | -64.5% |
| Rockwell Medical, Inc. (RMTI) | 2025-12-31 | $542.0K | -46.4% |
Compare CTMX, ABCL, ETON, BCYC side by side · Screen every company in Pharmaceutical Preparations ↗